Medical device manufacturers making cosmetic / aesthetic products.
Aesthetics products maker Allergan may be poised to take a larger piece of the facial filler market should the FDA approve its Juvederm Voluma XC injectable gel.
Aesthetics products giant Allergan (NYSE:AGN) is poised to add another 1st to its repertoire, as long as U.S. healthcare regulators green-light the company's Juvederm Voluma XC injectable gel for volume restoration in the mid-face.
Shares of medical aesthetics giant Allergan initially drop 13% on its Q1 results and a lowered earnings forecast, with shares rebounding toward the end of the week.
Allergan (NYSE:AGN) took a ride on the wild side this week as Wall Street pounded the medical aesthetics company after its 1st-quarter earnings release, initially sending share down more than 13%.
Some of the selloff appeared related to news that Irvine, Calif.-based Allergan is delaying the rollout of Darpin, its macular degeneration drug. Investors were also spooked by lowered guidance for 2013 and a bottom-line writedown over the sale of its Lap-Band business.
The FDA's General & Plastic Surgery Devices advisory panel votes unanimously that the benefits outweigh the risks for aesthetic medical device maker Allergan's Juvederm Voluma XC injectable gel.
An FDA advisory panel voted today to recommend approval for Allergan's (NYSE:AGN) Juvederm Voluma XC dermal filler for aesthetic volume restoration in the mid-face.
The FDA's General & Plastic Surgery Devices advisory panel unanimously decided that the injectable gel is safe, effective and that its benefits outweigh its risks.
Sales rose for Cynosure during the 1st quarter, but earning missed Wall Street's expectations by a wide margin, sending shares down.
First-quarter sales for Cynosure (NSDQ:CYNO) may have grown by a healthy 19%, but investors still sent share prices down some 2.2% today after the medical aesthetics company missed Wall Street's expectations by 1 thin dime.
Andrew Technologies wins clearance for analogous fat transfer for its HydraSolve liposuction procedure.
The FDA cleared a technique called analogous fat transfer for Andrew Technologies' HydraSolve liposuction procedure.
The technique allows surgeons to reinject a patient's own fat, gathered during the HydraSolve liposuction procedure.
HydraSolve uses a saline solution to liquefy fat tissue, a process called disaggregation. Analogous fat transfer maintains that fat tissue for injection into different parts of the body.
Louis Scafuri walks away from the corner office at aesthetic medical device company Syneron, making way for co-founder Shimon Eckhouse to take the reins as CEO.
After 4 years at the helm of Yokham, Israel-based Syneron Medical (NSDQ:ELOS), Louis Scafuri is walking away from the corner office of the aesthetic medical device company effective immediately.
Co-founder Shimon Eckhouse, who served as Syneron CEO from its founding in 1992 to 1999, was tapped to replace the outgoing Scafuri. Eckhouse will also serve as chairman, according to a press release.